Avanos Medical, Inc. executives and directors have only been selling lately: one insider sold about $165,000 of stock over 12 months, with no open-market purchases.
Selling on its own is common and often pre-planned (10b5-1 plans, taxes, diversification), so it matters more when it is unusually heavy or broad.
Quarter by quarter: No open-market insider buying or selling in the last full quarter. Insiders bought in 1 of the last 7 full quarters.
| Filed | Insider | Role | Type | Shares | Price | Value | Source |
|---|---|---|---|---|---|---|---|
| Nov 19, 2025 | Holbrook Kerr | Executive Officer | Sell | 305 | $11.02 | $3K | SEC |
| Nov 19, 2025 | Holbrook Kerr | Executive Officer | Sell | 100 | $11.01 | $1K | SEC |
| Nov 19, 2025 | Holbrook Kerr | Executive Officer | Sell | 13,834 | $11.00 | $152K | SEC |
| Nov 19, 2025 | Holbrook Kerr | Executive Officer | Sell | 761 | $11.01 | $8K | SEC |
| Aug 15, 2025 | BLACKFORD GARY | Director | Buy | 20,000 | $10.98 | $220K | SEC |
| Aug 15, 2025 | BLACKFORD GARY | Director | Buy | 40,000 | $11.00 | $440K | SEC |
| Mar 10, 2025 | Holbrook Kerr | Executive Officer | Sell | 7,000 | $15.25 | $107K | SEC |
| Mar 15, 2024 | Greiner Michael | CFO | Sell | 110 | $19.16 | $2K | SEC |
| Mar 15, 2024 | Greiner Michael | CFO | Sell | 808 | $19.15 | $15K | SEC |
| Mar 15, 2024 | Greiner Michael | CFO | Sell | 337 | $19.14 | $6K | SEC |
| Mar 15, 2024 | Greiner Michael | CFO | Sell | 2,231 | $19.13 | $43K | SEC |
| Mar 15, 2024 | Greiner Michael | CFO | Sell | 714 | $19.12 | $14K | SEC |
| Mar 15, 2024 | Greiner Michael | CFO | Sell | 3,800 | $19.11 | $73K | SEC |
| Mar 11, 2024 | Shimer Julie Ann | Director | Buy | 500 | $19.85 | $10K | SEC |
In the last 12 months Avanos Medical, Inc. insiders made open-market purchases worth about $0 and sales worth about $165,000. Data comes from SEC Form 4 filings, updated every 30 minutes on CapitalSnitch.
The most recent open-market insider trade in AVNS was filed on 2025-11-19.
No congressional trades in AVNS were reported in the past two years. The full list is free on CapitalSnitch.
Public-record data for research and education, not investment advice. Insider sales are often pre-planned (10b5-1). Congress data: Data derived from public disclosures filed under the Ethics in Government Act and the STOCK Act, republished free for public transparency and news reporting. Disclosures may lag the trade by 45 days or more and show amounts only as ranges. This data may not be used for credit rating, loan underwriting, solicitation of money (political, charitable or other), direct-mail or commercial targeting (5 U.S.C. 13107).